News

While immunotherapies continue to gain traction across multiple tumor types, including malignancies of the central nervous system, these agents are also associated with unique adverse events.

Compelling stories of esophageal cancer survivors.

Ninlaro (ixazomib) has been approved by the FDA in combination with Revlimid (lenalidomide) and dexamethasone as a treatment for patients with multiple myeloma who received at least one prior therapy.

In this interview to gain further insight into the flurry of FDA activity, Tim Turnham, executive director of the Melanoma Research Foundation, sheds light on the recent drug approvals and what's next for treating melanoma.

Women who develop ovarian cancer are more likely to have better outcomes if they took oral contraceptives prior to their diagnosis, according to a new study by researchers at Mayo Clinic.

Together, The Young Fellowship Grant and The Career Development Award total $200,000

While recent advances in breast cancer therapy have resulted in survival gains, many patients and survivors have an increased risk of cardiovascular adverse events following treatment.

Diagnosis and management guidelines.

The FDA granted an accelerated approval of the CD-38-targeted monoclonal antibody daratumumab (Darzalex)-the first monoclonal antibody to be approved for patients with multiple myeloma.

Many patients who have had melanoma do not conduct regular skin self-examinations, and those who do check themselves do not use sufficient tools or techniques.

The FDA has granted an accelerated approval for Tagrisso (osimertinib) to treat patients with advanced non–small cell lung cancer (NSCLC) positive the EGFR T790M mutation and whose disease worsened following a prior EGFR TKI.

Patients and practitioners can expect more personalized options for the treatment of polycythemia vera (PV), including more refined criteria for diagnosing symptomatic patients and identifying those at highest risk along with more therapies for treating a disease which carries a heavy symptom burden.

Despite growing interest in the financial burden of out-of-pocket cancer treatment costs, little is known about whether patients actually want to talk about costs with their oncology team.

Parenting a child with a life-threatening illness like cancer is associated with unique demands, but simultaneously raising healthy siblings can add yet another layer of complexity.

The FDA has approved Cotellic (cobimetinib) to be used in combination with Zelboraf (vemurafenib) to treat patients with metastatic or unresectable melanoma who carry the BRAFV600E/K mutation.

CancerCare, the leading national nonprofit organization providing free, professional support services to anyone affected by cancer, is pleased to announce the availability of co-payment assistance for pancreatic cancer patients through the CancerCare Co-Payment Assistance Foundation.

Patient engagement platform will provide support and empowerment while advancing blood cancer research

ASCO issues advice on NEPA for CINV.

For oncology practitioners fielding questions from patients and survivors about breast cancer or genetics research news they've read online or through social media, a recently-launched news and information rating resource hopes to make that process easier.

The incidence of oropharyngeal cancers is growing-now surpassing cervical cancer-and the increase is expected to continue over the next 30 years, particularly for men currently aged ≤40 years.

Despite its safeguarding purpose, a new study has found that nearly half of healthcare personnel contaminated themselves while removing personal protective equipment (PPE).

ASCO issues updated statement on its use and healthcare provider education.

Women at an elevated risk of breast cancer may be able to avoid preventive procedures with regular aerobic exercise, according to a new study published in Breast Cancer Research and Treatment.

Targeted agents, such as afatinib (Gilotrif) and erlotinib (Tarceva), ushered in a new paradigm for treating patients with non-small cell lung cancer (NSCLC) who have an EGFR mutation.

Accelerated partial breast irradiation (APBI) using multicatheter brachytherapy in patients with early-stage breast cancer was not inferior to conventional whole breast irradiation (WBI), according to a phase III study presented at the 2015 American Society for Radiation Oncology (ASTRO) Annual Meeting.

The FDA has expanded the approval of Yervoy (ipilimumab) to include adjuvant treatment of fully resected stage III melanoma. The treatment will apply to patients with pathologic involvement of regional lymph nodes >1 mm.

Rates are on the rise for both men and women.

The FDA has approved the first-in-class oncolytic viral therapy Imlygic (T-VEC; talimogene laherparepvec) for the local treatment of unresectable lesions of the skin and lymph nodes in patients with melanoma that recurred after initial surgery.

As a 9-year testicular cancer survivor, I know the value of health insurance coverage and I choose my plan very carefully.

A study published recently in the Journal of Geriatric Oncology found that as many as 1 in 4 senior oncology patients were using complementary or alternative medicines (CAM), and the authors note that few oncology clinicians are sufficiently aware of the alternative medicines their patients take.